Flexion Therapeutics to Present at Cowen and Company’s 36th Annual Health Care Conference

BURLINGTON, Mass., March 07, 2016 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will provide a company overview at Cowen and Company’s 36^th Annual Health Care Conference on Monday, March 7, 2016 at 2:00 p.m. EST at the at the Boston Marriott Copley Place. 

To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.

About Flexion Therapeutics

Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with OA. The company's lead product candidate, Zilretta, is being investigated for its potential to provide improved analgesic therapy for the millions of U.S. patients who receive IA injections for knee OA annually. The company is also investigating another product candidate, FX007, a locally administered TrkA receptor antagonist for post-operative pain.

Investor Contact
David Carey
Lazar Partners LTD
T: 212-867-1768 
[email protected]
 
Media Contact
Mariann Caprino
TogoRun
T : 917.242.1087 
[email protected]
 
Corporate Contact
Fred Driscoll
Chief Financial Officer
Flexion Therapeutics, Inc.
T: 781-305-7763
[email protected]